Researchers have focused on a certain molecule that could be used to combat blood sugar instability for patients with Type 2 diabetes, according to a recent study.
Though new classes of therapeutics have recently been approved, scientists are still looking for ways to ease diabetes complications.
The molecule is called kallikrein-1 (KLK-1), and it's part of the kallikrein-kinin system (KKS). Although it sounds complex, KKS is best known for its role in limiting inflammation and reducing blood pressure, but previous studies suggest that one part of the KKS, called bradykinin (BK), increases insulin insensitivity in rats. KLK-1 remains poorly researched and generally misunderstood.
For science buffs out there, KLK-1 is a glycoprotein that exists as a mixture of glycoforms. It has been shown to significantly lower insulin level, glucose level and blood pressure.
To further understand these glycoproteins, researchers designed a study involving KLK-1.
In the study, KLK-1 was produced in mice, and its activity was compared to the activity of another molecule acquired from the National Institute for Biological Standards and Control. The mice were then injected with KLK-1 for fasting blood glucose and oral glucose tolerance tests.
It's helpful to understand that normal fasting blood glucose is below 100 milligrams/deciliter, whereas a person with a blood glucose level of 126 mg/dL or higher indicates diabetes.
The results indicated that KLK-1 boosts glucose infusion rates in non-diabetic rats. A single dose may reduce fasting blood glucose in obese rats. In diabetic rats, the molecule dosing for seven days also increased fasting insulin levels. After the treatment, glucose levels in the diabetic rats remained lower than controls.
The study authors attributed these low glucose levels to a protective effect on beta cell function or the stimulation effect on insulin secretion.
While the research was only conducted on animals and has yet to be studied with humans, researchers believe the glycoprotein might show potential for patients with Type 2 diabetes, thanks to its possible anti-hyperglycemic effects. It might be worth keeping an eye out for DM199 in upcoming months as scientists continue to delve into its possible therapeutic benefits.
To learn more about diabetes treatments: